MicroRNAs (miRNAs) have been involved in the pathogenesis of different types of cancer; however, their function in pituitary tumorigenesis remains poorly understood. Cyclic-AMP-dependent protein kinase-defective pituitaries occasionally form aggressive growth-hormone (GH)-producing pituitary tumors in the background of hyperplasia caused by haploinsufficiency of the protein kinase's main regulatory subunit, PRKAR1A. The molecular basis for this development remains unknown. We have identified a 17-miRNA signature of pituitary tumors formed in the background of hyperplasia (caused in half of the cases by PRKAR1A-mutations). We selected two miRNAs on the basis of their functional screen analysis: inhibition of miR-26b expression and upregulation of miR-128 suppressed the colony formation ability and invasiveness of pituitary tumor cells. Furthermore, we identified that miR-26b and miR-128 affected pituitary tumor cell behavior through regulation of their direct targets, PTEN and BMI1, respectively. In addition, we found that miR-128 through BMI1 direct binding on the PTEN promoter affected PTEN expression levels and AKT activity in the pituitary tumor cells. Our in vivo data revealed that inhibition of miR-26b and overexpression of miR-128 could suppress pituitary GH3 tumor growth in xenografts. Taken together, we have identified a miRNA signature for GH-producing pituitary tumors and found that miR-26b and miR-128 regulate the activity of the PTEN-AKT pathway in these tumors. This is the first suggestion of the possible involvement of miRNAs regulating the PTEN-AKT pathway in GH-producing pituitary tumor formation in the context of hyperplasia or due to germline PRKAR1A defects. MiR-26b suppression and miR-128 upregulation could have therapeutic potential in GH-producing pituitary tumor patients.
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs of [19] [20] [21] [22] [23] [24] [25] nucleotides that negatively regulate gene expression at the post-transcriptional level. They target mRNA in a sequencespecific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and 3 0 untranslated region (UTR) region of their targets. 1 Increasing evidence indicates that miRNAs have distinct expression patterns among tissues and cells at different differentiation stages. Furthermore, several studies have shown that miRNAs are involved in different processes, including differentiation metabolism cell growth and apoptosis, 2 both in animals and plants. Increasing evidence indicates that several miRNAs are directly involved in the pathogenesis of several human cancers, including lung cancer, 3 breast cancer, 4 colon cancer, 5 Burkitt lymphoma 6 and thyroid cancer. 7 Moreover, recent studies revealed that deregulation of miRNAs were responsible for endocrine carcinogenesis, including pancreatic, parathyroid and pituitary tumors. 8, 9 Most of the pituitary tumors are benign neoplasms; they account for 10-15% of all intracranial tumors. 10 These tumors often release pituitary hormones, such as the growth hormone (GH), prolactin, adrenocorticotropic hormone, and b-subunit derivatives, such as thyroid stimulating hormone, folliclestimulating hormone and luteinizing hormone. What starts the formation of these tumors remains unknown; equally unclear is what makes these benign lesions acquire an aggressive behavior and spread through local invasion, despite the fact that they technically remain 'benign' as they almost never develop distal metastases. 11 Several deregulated miRNAs have been involved not only in pituitary cell proliferation and apoptosis, but also in neoplastic transformation. 11 Recently, Bottoni et al. 12 showed that miR-15a and miR-16 were expressed at lower levels in GH-and prolactinsecreting pituitary adenomas compared with normal pituitary tissue, were inversely correlated with tumor diameter, and were directly correlated with secretion of the antineoplastic cytokine p43. In addition, miR-132, miR-128a, miR-16 and let-7 expression have been found to be downregulated in pituitary adenomas relative to normal tissues. 13 Amaral et al. 14 identified that miR-145, miR-21, miR-141, let-7a, miR-150, miR-15a, miR-16 and miR-143 levels were suppressed in adrenocorticotropic hormone-secreting pituitary tumors relative to normal pituitary tissues. Collectively, all these data strongly suggest that miRNAs could potentially have an essential role as central regulators of pituitary tumorigenesis and could be potentially useful as clinical markers.
We studied a relatively unique setting in pituitary tumor formation, GH-producing tumors that develop in the setting of somatomammotroph hyperplasia. Mostly, this happens in the context cyclic-AMP-dependent protein kinase-defective glands but not exclusively. Patients with a germline mutation that leads to haploinsufficiency of the protein kinase's type 1A regulatory subunit, PRKAR1A, develop invariably GH-producing cell hyperplasia. 15 However, only 15% or less of these patients form an adenoma after a series of genomic events involving chromosomal translocations, deletions and amplifications that are unusual for benign tumors. 15, 16 Consequently, these tumors like others developing in the context of GH-producing cell hyperplasia (that is, in McCune-Albright syndrome and in other sporadic cases) tend to be aggressive and relatively resistant to medical therapies. 17, 18 Cells from PRKAR1A-defective tumors cultured in vitro are relatively dedifferentiated and pluripotential, expressing both somatomammotroph features (GH and prolactin) and b-subunit and its mature derivative hormones (thyroid stimulating hormone, luteinizing hormone and follicle-stimulating hormone). 18, 19 In our patients, we identified a novel miRNA-gene network regulating their tumor formation. Specifically, we found 17 miRNAs to be differentially expressed between their pituitary tumors and normal tissues. miRNA screen analysis revealed that suppression of miR-26b, which was the top upregulated miRNA in pituitary tumors, and upregulation of miR-128, which was the top downregulated miRNA in pituitary tumors, suppressed the colony formation ability and invasiveness of pituitary tumor cells. We identified that miR-26b and miR-128 controlled the pituitary cell properties through regulation of their direct targets, PTEN and BMI1, respectively. Interestingly, miR-128 through BMI1 binding on the PTEN promoter affected PTEN expression levels in pituitary tumor cells. This is the first demonstration of the involvement and therapeutic potential of miRNAs and the PTEN-AKT pathway in GH-producing pituitary tumor formation in the context of hyperplasia or due to germline PRKAR1A defects.
RESULTS
miRNA signature of GH-producing pituitary tumors We identified 17 miRNAs to be differentially expressed between tumors and normal pituitary tissues (Figure 1a) . Specifically, we found five miRNAs (miR-26b, miR-26a, miR-212, miR-107, and miR-103) to be upregulated and twelve miRNAs (miR-125b, miR-141, miR-144, miR-164, miR-145, miR-143, miR-15b, miR-16, miR-186, let-7b, let-7a3, and miR-128) to be downregulated in twelve pituitary tumors relative to five normal tissues. The miRNA array data were validated by performing miRNA real-time PCR (RT-PCR) analysis (Figure 1b, Supplementary Figure 1 ). Both analyses revealed that miR-26b (B6-fold) and miR-212 (B4-fold) were the top two upregulated miRNAs, while let-7a3 (B6-fold) and miR-128 (B7.5-fold) were the top two downregulated miRNAs in tumors relative to control tissues, suggesting their potential role in pituitary tumor formation.
MiR-26b and miR-128 regulate the tumorigenicity and invasiveness of pituitary cells To assess the functional role of these differentially expressed miRNAs, we tested whether inhibition of upregulated miRNAs or overexpression of downregulated miRNAs affect the tumorigenicity and invasiveness of pituitary cancer cells. Specifically, AtT-20 pituitary cancer cells were transfected with antisense miRNAs for the five upregulated miRNAs and with miRNA mimics for the twelve downregulated miRNAs and tested their ability to form colonies in soft agar (Figure 2a) . We found that the inhibitors against miR-26b and miR-26a and the overexpression of miR-128 inhibited 460% the ability of AtT-20 cells to form colonies in soft agar. In addition, we examined the effects of the differentially expressed miRNAs on pituitary cancer cell invasiveness. We transfected AtT-20 cells with antisense miRNAs for the five upregulated miRNAs and with miRNA mimics for the twelve downregulated miRNAs for 24 h and then cells were seeded in matrigel invasion plates (Pharmingen, Bedford, MA, USA, cat no 354480). After 16 h (total 40 h from the initiation of the experiment), we examined the invasive ability of these transfected cells (Figure 2b ). We identified that inhibition of miR-26b and miR26a and overexpression of miR-128 and miR-186 suppressed 460% of the invasive ability of AtT-20 cells (Figure 2c ). In addition to AtT-20 cells, we evaluated the effects of miR-26 inhibition and miR-128 overexpression in the soft agar colony and invasive ability of two (GH3, MtT/S) GH-secreting pituitary cell lines. We found that the combination of miR-26 suppression and miR-128 overexpression blocked the soft agar colony and invasive abilities of these cells (Figure 2d ). Overall, these data suggest that the inhibition of miR26b and overexpression of miR-128 has a combinatorial effect on suppressing the tumorigenicity and invasiveness of pituitary tumor cells. Interestingly, miR-26b is the highest upregulated miRNA while miR-128 is the top downregulated miRNA in human pituitary tumors relative to normal tissues.
Identification of miR-26b and miR-128 direct gene targets in pituitary cells We were interested in identifying miR-26b and miR-128 downstream direct targets in pituitary tumors. Bioinformatic analysis revealed that the top three identified direct gene targets according to the different criteria (described in Materials and methods) were PTGS2, PTEN and HMGA1 for miR-26b and MAPK14, PLK2 and BMI1 for miR-128 (Table 1) . Due to the fact that miRNAs frequently act as negative regulators of gene expression, we were interested in identifying if there is an inverse correlation between the miRNAs and these predicted direct gene targets. Thus, we tested the mRNA expression levels of these potential gene targets and identified an inverse correlation between miR-26b and PTEN (downregulated), and between miR-128 and BMI1 (upregulated) in our pituitary tumors ( Figure 3a ). To identify whether miR-26b and miR-128 regulate directly PTEN and BMI1, respectively, through binding in their 3
0 UTRs (Supplementary. Figure 2 ), we performed luciferase assay. Specifically the 3 0 UTRs of PTEN and BMI1 were cloned under luciferase, and luciferase activity was measured after overexpression of miR-26b and miR-128, respectively. We found that miR-26b overexpression inhibited 470% PTEN luciferase activity while miR-128 overexpression inhibited 480% of BMI1 luciferase activity in GH3 and MtT/S pituitary tumor cells, validating the direct interactions between miR-26b and PTEN and miR-128 and BMI1 in pituitary cells (Figure 3b ). Furthermore, overexpression of miR-26b blocked 480% PTEN mRNA levels while miR-128 overexpression blocked 460% BMI1 mRNA levels in GH3 and MtT/S pituitary tumor cells ( Figure 3c ). All these data suggest that miR-26b regulates directly PTEN expression levels while miR-128 regulates directly BMI1 expression levels in GH3 and MtT/S pituitary tumor cells. MiR-26b and miR-128 control pituitary tumor formation and cell invasiveness through regulation of their direct targets We were interested in studying if miR-26b and miR-128 controlled the ability of GH3, MtT/S and AtT-20 pituitary cells to form colonies in soft agar and to invade, through PTEN and BMI1, respectively. Inhibition of miR-26b resulted in suppression of GH3, MtT/S and AtT-20 colony growth; this suppression was blocked when PTEN was knocked down by small interfering RNA against PTEN (Figure 4a; Supplementary Figure 3a) . In addition, inhibition of miR-128 increased the ability of pituitary cells to form colonies in soft agar while inhibition of BMI1 by small interfering RNA blocked this effect. We got similar data when we tested the invasiveness of these cells in the same experimental conditions (Figure 4b ; Supplementary Figure 3b) , suggesting that miR-26b and miR-128 regulate the invasiveness and colony formation of GH3, MtT/S and AtT-20 cells through regulation of their direct downstream targets.
MiR-26b and miR-128 regulate PTEN-AKT pathway in pituitary cells We were interested in testing if there is any synergy between miR-26b and miR-128 affecting pituitary tumor formation and/or progression. We found that the combination of inhibition of miR-26b and upregulation of miR-128 had a more potent effect on suppressing colony formation and invasiveness of GH3 and MtT/S cells ( Figure 5a ) and AtT-20 cells (Supplementary Figures 4a, b) .
Due to the fact that inhibition of miR-26b and upregulation of miR-128 had very similar effects, we examined if there was a molecular link between miR-26/PTEN and miR-128/BMI1 signaling pathways in the pituitary tumor cells. Interestingly, a recent study has shown that BMI1 is a transcriptional suppressor of PTEN expression levels in nasopharyngeal carcinomas. 20 Thus, we examined if BMI1 regulated the expression of PTEN in pituitary GH3 cells by performing chromatin immunoprecipitation analysis with an antibody against BMI1 followed by PCR analysis in the promoter region of PTEN in GH3 and AtT-20 cells. We found that inhibition of miR-128 resulted in increased binding of BMI1 in GH3 and AtT-20 cells (Figure 5b; Supplementary Figure 4c ). Then, we tested PTEN mRNA levels by RT-PCR analysis. We identified that the inhibition of miR-128 resulted in suppression of PTEN mRNA levels in GH3, MtT/S and AtT-20 cells (Figure 5c; Supplementary  Figure 4d ). The combination of inhibition of miR-128 and overexpression of miR-26b blocked even more effectively PTEN mRNA levels.
Overall, these data suggested that both miR-128 (through BMI1 binding) and miR-26b (directly) regulated PTEN expression levels in pituitary AtT-20 cells. It is well-known that PTEN is a negative regulator of the AKT signaling pathway in multiple cancers. We found that inhibition of miR-128 and overexpression of miR-26b resulted in increased AKT activity (S473 phosphorylation levels) in GH3, MtT/S and AtT-20 cells (Figure 5d; Supplementary Figure 4e) . These data suggested that miR-128 and miR-26b regulate PTEN-AKT pathway in pituitary cancer. To examine the role of the miR-128/miR-26/PTEN-AKT axis in our pituitary tumors, we studied the effects of miR-128 and/or miR-26b in the presence or absence of PTEN. We identified that suppression of PTEN expression by small interfering RNA, blocked the inhibitory effects on colony formation and invasiveness of miR-26b downregulation and miR-128 upregulation in GH3, MtT/S and AtT-20 cells , the mice were randomly distributed in six groups (untreated or treated intratumorally with miRNAs). We found that GH3 tumor growth was suppressed 83% in the mice that were treated with as-miR-26b and miR-128 ( Figure 6a ). Furthermore, our data revealed that AKT phosphorylation levels were more efficiently suppressed in the GH3 tumors (day 40) treated with as-miR-26b and miR-128 (Figure 6b ), suggesting that these miRNAs control pituitary tumor growth through the regulation of the AKT pathway.
The miR-26b/miR-128/PTEN pathway in the GH-producing pituitary tumors We finally tested in the 12 human pituitary tumors the expression levels of the different members of the signaling pathway that we identified above. We found an inverse correlation between (Figure 6c ), suggesting the human relevance of this miRNA signaling pathway in GH-producing pituitary tumors developing from somatomammotroph hyperplasia.
DISCUSSION
In the past few years, several miRNAs have been implicated in various human cancers. Both losses and gains of miRNAs function have been shown to contribute to cancer development through different mechanisms. To characterize the miRNAome of pituitary oncogenesis, initially we analyzed miRNA expression levels in a unique setting, that of relatively aggressive GH-producing tumors, developing in the context of pituitary somatomammotroph hyperplasia. We found 17 miRNAs differentially expressed, and among them, two that ended up being involved in the same pathway controlling PTEN/AKT signaling. MiR-26 and miR-212 were the top upregulated miRNAs while miR-16, let-7a3 and miR-128 were the top downregulated miRNAs in the studied pituitary tumors relative to normal tissues. Previous studies have linked these miRNAs with the pathogenesis of different types of cancer through regulation of key gene targets. Specifically, miR-15 and miR-16 have been found to act as tumor suppressors through regulation of the anti-apoptotic BCL2. 21 In addition, let-7 family members are downregulated in different cancer types and directly target several oncogenes such as KRAS, HMGA2 and IL-6.
22-24
Furthermore, miR-26 suppresses tumorigenesis in c-Myc-driven B lymphoma cells 25 and is located on chromosome 3p21.3, which is frequently deleted in small-cell lung carcinomas, renal cell carcinomas and breast carcinomas. 26 Recently, miR-212 downregulation has been found to be involved in lung cancer response to chemotherapy. 26 Furthermore, Incoronato et al.
27
suggested that miR-212 acts as a tumor suppressor through direct regulation of anti-apoptotic protein phosphoprotein enriched in diabetes (PED). All these data suggest that the deregulated miRNAs in pituitary tumors are also involved in the pathogenesis of other cancer types.
Molecular analysis revealed that miR-26b and miR-128 regulate the expression levels of PTEN and BMI1 in pituitary tumor cells. Previous studies have revealed that these miRNAs regulate PTEN and BMI1 genes in gliomas, 28, 29 suggesting that these miRNAgene interactions exist in different tumor types. PTEN is one of the most frequently mutated tumor suppressor genes in human cancers, leading to the activation of the PI3K/AKT signaling pathway and increased cell survival and oncogenesis. [30] [31] [32] Numerous reports suggest that the transcriptional role of PTEN lies at a key position in a complex network of tumor suppressor and oncogenes that regulate cellular transformation. Specifically, stress kinase pathways such as MEKK4 and JNK promote resistance to apoptosis, suppressing PTEN transcription activity by direct binding of NF-kB to the PTEN promoter. 33 Similarly, deregulation of BMI1 has been found to alter cell proliferation, apoptosis, senescence and stem cell self-renewal [34] [35] [36] [37] and correlated with the invasive and metastatic phenotype of several human cancer types. [38] [39] [40] Furthermore, BMI1 is a member of the Polycomb group family of proteins. 37 The Polycomb group proteins function within distinct multi-subunit complexes and epigenetically regulate gene expression by altering chromatin states at specific promoters. 37, 39 Our analysis identified that miR-128, which targets BMI1 expression, also affected PTEN expression levels. Interestingly, we found that BMI1 binds in the promoter region of PTEN, suppressing its expression levels. Consistent with our data, a previous study has shown that BMI1 represses PTEN by binding to the PTEN promoter locus. 20 Overall, miRNAs and transcription factors have a critical regulatory role in tumor formation and/or progression. Like transcription factors, miRNAs are trans-acting molecules that interact with a number of other regulatory elements. They, thus, generate a complex grid of communications between signaling pathways 41 that are uncovered only after studies like the one reported here. In this investigation, the unexpected involvement of a miRNA-PTEN-AKT pathway in GH-producing pituitary tumors was uncovered. Furthermore, our data propose that combinatorial inhibition of miR-26b and overexpression of miR-128 could have therapeutic potential in GH-producing pituitary tumors. These findings should be followed by experiments in additional animal models of pituitary oncogenesis in order to evaluate the potential use of these miRNAs or of PTEN-AKT-targeting molecules in vivo and in vitro that may lead to new therapies for patients with aggressive GH-producing pituitary tumors.
MATERIALS AND METHODS

Subjects and DNA studies
Twelve human pituitary tumors and five normal pituitary tissues were collected, the latter from unidentified human cadavers. All normal tissues were examined histologically for any lesions before use in this experiment and screened negative for all genes that the twelve tumors were screened for (see below). Tissue from all patients was collected at surgery under research protocols approved by the Institutional Review Board of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Tissues from these patients and the normal control tissues have been used in our previous studies 15, 16, 18, 19, [42] [43] [44] and their histology and clinical cases have been extensively presented. 15, 16, 18, 19, 44 All tumors met the criteria for GH-producing tumors surrounded by hyperplasia 15, 18, 45 and also stained positively for both prolactin and GH, which identified them of being of the somatomammotroph lineage. All tumors with PRKAR1A-mutations displayed loss of heterozygosity for the PRKAR1A locus on 17q22-24. 15, 42, 44, 46 All tumor samples were sequenced for activating mutations in the GNAS gene and were found to be negative. 42 In addition to PRKAR1A, 44, 46 all peripheral DNA samples of the patients were sequenced for the AIP, MEN1, CDKN1B and CDKN2C genes and were found to be negative for any coding sequence mutations. 42 The case of patient 2 has been published as a single patient report; 47 he was also sequenced for PTEN mutations with negative results. Cells from the tumor of patient 5 were the ones studied in vitro previously. 19 Patients 2, 4, 6 and 7-12 had no PRKAR1A-mutations; patients 1, 3 and 5 carried the c.491_492delTG/p.Val164fsX4, c.693insT/p.Arg232X, and c.693insT/ p.Arg232X (same as patient 1, but from an unrelated family) mutations, respectively. These mutations lead to non-sense mRNA-mediated decay of the mutant allele and, thus, in combination with the loss of heterozygosity of the normal allele lead to no expression of the PRKAR1A gene in pituitary tumor tissues, as we have demonstrated elsewhere. 44, 46 miRNA expression analysis
The RNA isolation was performed using the mirVana miRNA isolation Kit (Ambion, Inc., Austin, TX, USA) according to the manufacturer's instructions. TaqMan miRNA array assays were used in order to study the expression levels of 365 miRNAs in twelve pituitary tumors and five normal pituitary tissues.
miRNA RT-PCR analysis
We validated our results with RT-PCR, using the miRvana quantitative RT-PCR miRNA detection kit and quantitative RT-PCR primer sets, according to the manufacturer's instructions (Ambion, Inc.). We used the U6 small nuclear RNA as internal control. RT-PCR experiments were performed in triplicate and the data are presented as mean±s.d.
Cell culture GH3 (GH-secreting) rat pituitary tumor cells, MtT/S (GH-secreting) rat somatotrophic pituitary tumor cells and AtT-20 (adrenocorticotropic hormone-secreting) mouse pituitary cells were cultured in Dulbecco's modified Eagle's medium (Life Technologies, Inc., Gaithersburg, MD, USA) supplemented with 10% FCS, 2.2 g/l NaHCO 3 , 10 mmol/l HEPES, 2 mmol/l glutamine, 5 mg/l insulin, 5 mg/l transferrin and 100 U/l penicillin/ streptomycin.
Colony formation assay
AtT-20 pituitary tumor cells were transfected with 50 nM antisense miRNAs (as-miR-26b, as-miR-26a, miR-128, as-miR-212, as-miR-107, as-miR-103) for the five upregulated miRNAs and with 50 nM miRNA mimics (miR-125b, miR-141, miR-144, miR-164, miR-145, miR-143, miR-15b, miR-16, miR-186, let-7b, let-7a3, miR-128) for the twelve downregulated miRNAs for 48 h. In addition, GH3 and MtT/S pituitary tumor cells were transfected with asmiR-26b or as-miR-26a or miR-128 for 48 h. Then, samples in triplicate of 10 5 cells were mixed 4:1 (v/v) with 2.0% agarose in growth medium for a final concentration of 0.4% agarose. The cell mixture was plated on top of a solidified layer of 0.5% agarose in growth medium. Cells were fed every 6-7 days with growth medium containing 0.4% agarose. The number of colonies was counted after 20 days. The experiment was repeated thrice and the statistical significance was calculated using Student's t-test.
Invasion assays
AtT-20 cells were transfected with 50 nM antisense miRNAs (as-miR-26b, as-miR-26a, miR-128, as-miR-212, as-miR-107, as-miR-103) for the five upregulated miRNAs and with 50 nM miRNA mimics (miR-125b, miR-141, miR-144, miR-164, miR-145, miR-143, miR-15b, miR-16, miR-186, let-7b, let7a3, miR-128) for the twelve downregulated miRNAs for 24 h. In addition, GH3 and MtT/S pituitary tumor cells were transfected with as-miR-26b or as-miR-26a or miR-128 for 24 h. Invasion of matrigel has been conducted by using standardized conditions with BDBioCoat growth factor reduced MATRIGEL invasion chambers (Pharmingen). Assays were conducted according to the manufacturer's protocol, by using 10% FBS as chemoattractant. Non-invading cells on the top side of the membrane were removed while invading cells were fixed and stained with 4 0 -6-diamidino-2-phenylindole (DAPI, Vector Laboratories Inc., Burlingame, CA, USA), 16 h post seeding. In all assays, 10 fields per insert were scored and s.d. was measured. The experiment was repeated thrice and the statistical significance was calculated using Student's t-test.
miRNA target prediction methods
We used three databases to detect the putative miRNA-gene targets: miRBase (http://microrna.sanger.ac.uk), miRanda (http://www.microrna.org) and TargetScan version 5.2 (http://www.targetscan.org/index.html) databases. Then, we selected the commonly predicted miRNA targets from the three databases and those that were conserved in other species, aiming to the higher biological significance of our results. Studies were then planned according to known pathway interactions per miRNA family. [20] [21] [22] [23] miRNA transfection experiments GH3, MtT/S and AtT-20 pituitary cells were seeded in six-well plates and were transfected with 50 nM miR-26b or as-miR-26 or miR-128 or as-miR-128 (Ambion, Inc.) using siPORT NeoFX transfection kit. siPORT NeoFX is a lipid transfection agent consisting of a mixture of lipid that spontaneously forms a complex of miRNAs and facilitates its transfer to target cells. Transfection with 50 nM of scramble negative control miRNA was used as an internal control. No cell toxicity was detected due to the transfection agent (data not shown). RNA was extracted 48 h after miRNA transfection and RT-PCR analysis was performed as described above. RT-PCR experiments were performed in triplicate and the data are presented as mean±s.d.
Luciferase reporter assay GH3 and MtT/S pituitary cells in 24-well plates were transfected using Fugene6 (Roche, Penzberg, Germany). Fifty nanometers of miR-26b or miR-128, the firefly luciferase reporter gene construct (PTEN 3 0 UTR in pEZX-MT01 (T051204, Genecopoeia Inc.) vector or BMI1 3 0 UTR in pEZX-MT01 vector (T026649, Genecopoeia Inc.)) (200 ng) and 1 ng of the pRL-SV40 Renilla luciferase construct (for normalization) were co-transfected per well. Cell extracts were prepared 24 h after transfection, and the luciferase activity was measured using the Luc-Pair miRNA Luciferase Assay Kit (Genecopoiea Inc., Rockville, MD, USA). Luciferase reporter assays were performed in triplicate and the data are presented as mean ± s.d.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was carried out as described previously. 48, 49 Briefly, the chromatin fragments, derived from untreated, 50 nM as-miR-NC or as-miR-128a treated (24 h) GH3 rat and AtT-20 mouse pituitary cells, were immunoprecipitated with 6 mg of antibody against BMI1. DNA extraction was performed using Qiagen Purification Kit (Qiagen, Valencia, CA, USA). RT-PCR analysis was performed for BMI1 binding site in the PTEN rat promoter area using the following primers: forward 5 0 -CT CTGGCTGCTGAGGAGAAG-3 
Mouse experiments
In all, 5 Â 10 6 GH3 pituitary cells were injected subcutaneously in the right flank of athymic nude mice (Charles River Laboratories, Wilmington, MA, USA). Tumor growth was monitored every 5 days and tumor volumes were calculated by the equation V (mm 3 ) ¼ ab 2 /2, where a is the largest diameter and b is the perpendicular diameter. When the tumors reached a size of B100mm 3 (day 25) were randomly distributed in six groups (3 mice/group). The first group was used as control (untreated), the second group was intratumorally (i.t.) treated with 5mg/kg miR-NC, the third group was i.t. treated with 5mg/kg as-miR-NC, the fourth group was i.t. treated with 5mg/kg as-miR-26b, the fifth group was i.t. treated with 5mg/kg miR-128 and the sixth group was i.t. treated with 5mg/kg of as-miR-26b and 5mg/kg of miR-128. The miRNAs were purchased by Ambion and were filtered through a 0.2-mm pre-sterilized filter and tested for the presence of endotoxin. Next, we mixed the miRNAs with Invivofectamine 2.0 liposomes (Ambion Inc.) and injected them in mice in a volume of 100ml using a 20-G needle. The experiments described above were performed in accordance with Dana-Farber Institutional Animal Care and Use Committee procedures and guidelines.
Statistical analysis
A two-sample t-test was done for experiments described above. Experiments were done at least in triplicate, and a mean was calculated. A P-value of o0.05 was considered significant.
